Skip to content

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
  • Home
  • About
    • NIH Collaboratory
      • Coordinating Center
      • NIH Collaboratory Trials
      • Core Working Groups
      • Steering Committee
      • Distributed Research Network
      • Our Impact
    • Living Textbook
      • Table of Contents
      • How to Use This Site
  • Resources
    • Data and Resource Sharing
    • Training Resources
    • Tools for Researchers
    • Publications
    • Knowledge Repository
  • Webinar
  • Podcast
  • News
    • News Feed
    • Calendar
    • Subscribe
return to home
Subscribe to Newsletter go to twitter feed go to linkedin go to blue sky feed
Search
NIH Collaboratory
Living Textbook of
Pragmatic Clinical Trials

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
home button

Rethinking Clinical Trials

A Living Textbook of Pragmatic Clinical Trials

  • Design
    • What is a Pragmatic Clinical Trial?
    • Decentralized Pragmatic Clinical Trials
    • Developing a Compelling Grant Application
    • Experimental Designs and Randomization Schemes
    • Endpoints and Outcomes
    • Analysis Plan
    • Using Electronic Health Record Data
    • Building Partnerships and Teams to Ensure a Successful Trial
    • Intervention Delivery and Complexity
    • Patient Engagement
  • Data, Tools & Conduct
    • Assessing Feasibility
    • Acquiring Real-World Data
    • Assessing Fitness-for-Use of Real-World Data
    • Study Startup
    • Participant Recruitment
    • Monitoring Intervention Fidelity and Adaptations
    • Patient-Reported Outcomes
    • Clinical Decision Support
    • Mobile Health
    • Electronic Health Records–Based Phenotyping
    • Navigating the Unknown
  • Dissemination & Implementation
    • Data Sharing and Embedded Research
    • Dissemination Approaches for Different Audiences
    • Implementation
    • End-of-Trial Decision-Making
  • Ethics & Regulatory
    • Privacy Considerations
    • Identifying Those Engaged in Research
    • Collateral Findings
    • Consent, Disclosure, and Non-Disclosure
    • Data and Safety Monitoring
    • Ethical Considerations of Data Sharing in Pragmatic Clinical Trials
    • Ethics for AI and ML
    • IRB Responsibilities and Procedures

Working With an External IRB

CHAPTER SECTIONS

IRB Responsibilities and Procedures


Section 4

Working With an External IRB

Expand Contributors

Pearl O’Rourke, MD
Luke Gelinas, PhD

Contributing Editor

Damon M. Seils, MA

As noted previously, IRB approval can be obtained from an institution’s internal IRB or from an external IRB, such as an independent IRB or an IRB at another institution. The IRB completing the review is the “reviewing IRB,” and the institutions that rely on the external IRB are the “relying institutions.”

The requirements for the reviewing IRB and the relying institution are the same whether the project is using an sIRB for multisite research or an external IRB for a single-site study.

The main goal of using an sIRB for multisite research is to streamline the review process by eliminating duplicative and potentially conflicting reviews at the clinical trial sites. There has been a dramatic increase in the use of the sIRB review model in response to the 2016 NIH policy requiring sIRB review for NIH-funded multisite research (NIH 2016) and the requirement for sIRB review of cooperative research set forth in the revised Common Rule (45 CFR §46).

When a study uses  sIRB review, the investigators must identify an IRB to serve as the reviewing IRB (or the “IRB of record") for the study. The proposed IRB must agree to serve in this role, and of note, an IRB can refuse to serve as an sIRB.

Participating sites must agree to use the designated sIRB and complete a formal institutional reliance agreement which cedes IRB review to the reviewing IRB. As noted below, the relying institutions retain several responsibilities beyond IRB approval.

The relying institutions rely on the sIRB for review and approval of the protocol but maintain responsibility for all other institutional requirements, which must be completed and then communicated to the reviewing IRB. This collaboration allows the sIRB to include such site-specific information in the review of the protocol. The specific institutional responsibilities vary by study based on the nature of the research being conducted. These institutional responsibilities can include:

  • Review and approval of local non-IRB institutional committees—often called ancillary reviews—such as radiation safety, pharmacy, nursing, biosafety, and data security
  • Assessment of competency of investigators and staff to conduct the research and review and management of any investigator or institutional conflicts of interest
  • Assessment of adequacy of local resources for conducting the research
  • Identification of local context issues that may affect the conduct of the research that need to be communicated to the reviewing IRB, such as local standards of care, local laws, and characteristics of the local population
  • Institutional policies, such as processes for handling noncompliance and assessments of conflict of interest

In most institutions, the local IRB office or human research protection program (HRPP) office routinely coordinates and/or documents the myriad institutional reviews. The reviews are usually triggered by submission of a protocol to the local IRB office. In most situations, when an institution cedes IRB review to an external IRB, an application still must be submitted to the local IRB office or HRPP office to initiate and monitor the necessary reviews and institutional signoffs via a required “local context review.” This means that the site investigator must work with both the sIRB and their own local IRB or HRPP office and be certain that the sIRB receives documentation of the institution-specific information.

While local site review is conducted by the local IRB or HRPP office, this review does not constitute a review by an IRB committee and is not designed to assess whether the study meets the criteria for IRB approval. The formal IRB review remains the responsibility of the sIRB.

The reviewing IRB is responsible for all IRB actions during the life of the protocol, including:

  • Continuing review
  • Review of all protocol amendments
  • Review of any unanticipated events
  • Handling participant questions and complaints
  • Consideration and required review of deviations and noncompliance
  • Closure of the protocol upon completion of the study

The relying institution remains responsible for ongoing local context review throughout the life of the study. This may include:

  • Review of protocol amendments if a local context issue is triggered, such as:
    • The amendment requires additional review by an institutional ancillary committee
    • The amendment involves addition of new research staff that require review of credentials, training, or conflicts of interest
    • The amendment has implications for local state laws or institutional policies and adherence with regulatory or policy requirements must be addressed
  • Coordination with the reviewing IRB for addressing incidents of noncompliance if local institutional research personnel are involved in the possible noncompliance or if the noncompliance results in changes to or termination of the research
  • Coordinating with the reviewing IRB to handle local participant questions and/or complaint
  • Maintaining records of institutional research activity (meaning that relying institutions must be aware when the research is completed or otherwise terminated)

Previous Section Next Section

SECTIONS

CHAPTER SECTIONS

sections

  1. Introduction
  2. Organization of the IRB
  3. IRB Actions
  4. Working With an External IRB
  5. FDA Regulations and the IRB

Resources

The Common Rule
Information about the Common Rule from the Office of Human Research Protections

Clinical Trials and Human Subject Protection
Information about human subjects protection from the FDA

The HIPAA Privacy Rule
Summary, guidance, and other resources from the US Department of Health and Human Services

REFERENCES

back to top

NIH. 2016. Final NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research. NOT-OD-16-094. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-094.html

back to top


Version History

Published September 26, 2025

current section :

Working With an External IRB

  1. Introduction
  2. Organization of the IRB
  3. IRB Actions
  4. Working With an External IRB
  5. FDA Regulations and the IRB

Citation:

O'Rourke P, Gelinas L. IRB Responsibilities and Procedures: Working With an External IRB. In: Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials. Bethesda, MD: NIH Pragmatic Trials Collaboratory. Available at: https://rethinkingclinicaltrials.org/chapters/ethics-and-regulatory/irb-responsibilities-and-procedures/working-with-an-external-irb/. Updated October 3, 2025. DOI: 10.28929/283.

Footer Menu

  • How to Use This Site
  • About NIH Collaboratory
  • Enrollment Reporting
  • Grand Rounds
  • Funding Statement
Link to Twitter Link to LinkedIn Link to Blue Sky Link to NIH Collaboratory email

Reference in this Web site to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation by the U.S. Government or National Institutes of Health (NIH). NIH is not responsible for the contents of any “off-site” Web page referenced from this server.

Log in
Privacy Statement
WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly. Site Map